StockData
Rein Therapeutics, Inc. logo

Rein Therapeutics, Inc. (RNTX) stock

RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.36−0.04 (-10.90%)

Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%

Earnings

Rein Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q1 FY2025
–
EPS, Q1 FY2025
-$0.25
-$0.86 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Rein Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2025ended Mar 31, 2025May 15, 2025during market hours––-$0.25Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024during market hours––-$0.27Release
Q2 FY2024ended Jun 30, 2024Aug 14, 2024during market hours––-$0.45Release
Q1 FY2024ended Mar 31, 2024May 15, 2024during market hours––-$0.86Release
Q4 FY2023ended Dec 31, 2023Apr 15, 2024during market hours––-$1.54Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Rein Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Rein Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Rein Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. News
  2. Update
  3. News
  4. News
  5. News
  6. News
  7. Results
  8. Results
  9. Results
  10. Results
  11. News
  12. Results
  13. Update
  14. Update
  15. Update

See a number that looks wrong?